Drug, bio-affecting and body treating compositions inventions 02/07

20070041900 - Method and device for radiotherapy: A radiotherapy method, comprising positioning a predetermined amount of a radionuclide selected from the group consisting of Radium-223, Radium-224, Radon-219 and Radon-220, in proximity to and/or within a tumor of a subject, for a predetermined time period. The predetermined amount and the predetermined time period are selected sufficient for the... Agent: Martin Moynihan Prtsi Inc

20070041899 - Radiolabelled substrates: The present invention relates to radiolabelled P-glycoprotein (P-gp) substrates, which are useful for the labeling and diagnostic imaging of P-gp functionality.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070041901 - Stabilized aptamers to psma and their use as prostate cancer therapeutics: The present invention provides stabilized, high affinity nucleic acid ligands to PSMA. Methods for the identification and preparation of novel, stable, high affinity ligands to PSMA using the SELEX™ method with 2′-O-methyl substituted nucleic acids, and cell surface SELEX™ are described herein. Also included are methods and compositions for the... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070041903 - Modified minigastrin analogs for oncology applications: The invention is directed to modified minigastrin analogs. It further relates to labeling such modified minigastrin analogs with metallic radionuclides. The invention further relates to methods for making such novel modified minigastrin analogs, their labeling with metallic radionuclides and their use in oncology applications as in the targeted diagnostic imaging... Agent: George Georgellis

20070041904 - Peptides whose uptake by cells is controllable: A generic structure for the peptides of the present invention includes A-X-B-C, where C is a cargo moiety, the B portion includes basic amino acids, X is a cleavable linker sequence, and the A portion includes acidic amino acids. The intact structure is not significantly taken up by cells; however,... Agent: Townsend And Townsend And Crew, LLP

20070041902 - Somatostatin analogs with inhibitory activity to growth hormone release: Provided are therapeutic and diagnostic somatostatin analogs including radiotherapeutic and radiodiagnostic Reagents, and methods of making and use thereof.... Agent: Buchanan, Ingersoll & Rooney LLP

20070041905 - Method of treating depression using a tnf-alpha antibody: The invention describes methods of treating depression comprising administering a TNFα antibody, such as a human TNFα antibody. The invention also provides a method for treating depression comprising inhibiting TNFα activity in a subject suffering from depression by systemically administering to the subject a human anti-TNFα antibody, or an antigen-binding... Agent: Lahive & Cockfield, LLP

20070041908 - Injectable composite for the magnetocytolysis of bone metastatic cells: The invention relates to a degradable, biocompatible material which is made from a phosphocalcic cement comprising magnetic particles. Said material can be used to treat bone metastases by means of thermolysis and/or to mark cancer cells.... Agent: Foley And Lardner LLP Suite 500

20070041909 - Nanoparticulate probe for in vivo monitoring of tissue oxygenation: A new class of micro- and nano-particulate paramagnetic spin probes useful for magnetic resonance imaging techniques, including electron paramagnetic resonance (EPR) and magnetic resonance imaging (MRI). The probes are lithium phthalocyanine derivative compounds. Also provided are suspensions and emulsions comprising lithium phthalocyanine derivative probes. Also provided are noninvasive methods for... Agent: Joan N. Drew

20070041906 - Bone substitute composition: An injectable bone mineral substitute material composition with the capability of being hardened in a body fluid in vivo, which comprises at least one calcium phosphate component and at least one calcium sulfate component as a dry mixture mixed with an aqueous liquid, and at least one accelerator, the at... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070041907 - Immunoglobulin molecules with improved characteristics: The present invention provides for IgG1 molecules with improved characteristics. In particular, substitution mutations are provided that, in combination, facilitate improved placental transfer, improved serum half-life and improved FcRn binding. Substitution mutations are also provided, that in combination, can be used to block FcRn function and thereby increase the clearance... Agent: Fulbright & Jaworski L.L.P.

20070041911 - Hfc solution formulations containing salbutamol hydrochloride or salbutamol citrate: This invention relates to stabilized aerosol solution formulations containing acid addition salts of salbutamol, which are suitable for administration by metered dose inhalers (MDIs). More particularly, this invention relates to solution formulations containing one of the aforementioned salts of salbutamol, preferably salbutamol hydrochloride or salbutamol citrate, more preferably one of... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070041910 - Pharmaceutical spray compositions comprising a bioactive agent, at least one volatile silicone and a non-volatile oily phase: Sprayable pharmaceutical compositions suited for improved transdermal penetration contain a) at least one bioactive agent, notably at least one derivative of vitamin D, (b) at least one volatile silicone and c) a non-volatile oily phase, formulated into d) a pharmaceutically acceptable vehicle therefor.... Agent: Buchanan, Ingersoll & Rooney PC

20070041912 - Trospium containing compositions: The invention relates to a method for treating a disease characterized by a constrictive airway comprising administering to a patient in need thereof via inhalation a pharmaceutical composition comprising trospium, wherein said patient achieves an effective therapy for at least 10 hours. The trospium composition is preferably a particulate formulation... Agent: Elmore Patent Law Group, PC

20070041914 - Inhibition of bacterial deposition on oral surfaces: one of A and A′ is a hydrogen atom and the other is selected from a hydrogen atom or a group —(X)nRm; wherein n is i\selected from 0 or 1; provided that when n is 0, m is 1, and when n is 1, m is an integer of 1... Agent: Colgate-palmolive Company

20070041913 - Tooth coating composition: The invention provides a tooth coating composition for beauty and appearance and prevention of dental caries and excellent in the quick drying property, durability, color tone, luster, and removal easiness by using shellac and rosin as main components and a pigment, a pigment dispersant, a dye, an efficacious component having... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070041916 - Preparation containing diol: The invention is a cosmetic or dermatological formulation comprising a) at least one polyol in a concentration of from 0.1 to 20% by weight, based on the total weight of the formulation, and b) at least one diol selected from the group consisting of 2-methyl-1,3-propanediol, pentanediol, and hexanediol, in a... Agent: Alston & Bird LLP

20070041917 - Sunless tanning compositions: e

20070041915 - Use of a biguanide derivative for protecting skin against uvb radiation: The invention relates to the use of a bigaunide derivative for protecting skin against UVB radiation harmful effects and/or for protecting skin against undesirable and/or inaesthetic effects of UVB radiation.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070041918 - Enhanced boron nitride composition and polymer-based compositions made therewith: A boron nitride composition having its surface treated with a coating layer comprising a zirconate coupling agent. The boron nitride composition can be used as fillers in polymeric compounds at levels of up to 90 wt. %, giving thermal conductivity of up to 35 W/mK.... Agent: Geam - QuartzIPLegal

20070041919 - Cosmetic composition: b

20070041920 - Lip makeup composition with good staying power comprising a low molecular weight resin: The present disclosure relates to a lip makeup composition comprising at least one resin chosen from rosins, rosin derivatives and hydrocarbon-based resins, and mixtures thereof, wherein the at least one resin has a number-average molecular mass of less than or equal to 10,000 g/mol, and wherein the lip makeup composition... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070041923 - Body recessed portion cleaning agent: A body cavity cleansing agent of the present invention is either poured into or applied to a navel cavity (N) or an ear hole and solidifies after a specified period of time, and the cleansing agent takes a form that can be removed from the navel cavity (N) or the... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070041929 - Hair conditioning composition comprising silicone polymers containing quaternary groups: A hair conditioning composition comprising silicone polymer containing quaternary groups and a gel matrix. The composition of the present invention can provide improved conditioning benefits such as smooth feel and reduced friction to both damaged hair and non-damaged hair, while providing other benefits such as slippery and slick feel on... Agent: The Procter & Gamble Company Intellectual Property Division

20070041928 - Methods for removing make-up compositions from keratin materials: The invention relates to kits and methods for removing a long wearing or transfer resistant make-up composition from keratin materials such as eyelashes, nails, skin or lips, wherein the make-up composition contains at least one oil soluble film-forming agent and at least one coloring agent, including applying to the make-up... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070041930 - Use of quaternary polysiloxanes in cleaning and care compositions: The invention relates to the use of polysiloxanes which comprise a plurality of quaternary ammonium groups in the molecule in cosmetic or pharmaceutical compositions for the cleaning and care of keratin fibers, in particular of human hair. The improvement in the shine and in the color protection of the hair... Agent: Clariant Corporation Intellectual Property Department

20070041924 - Sebum control compositions based on saponins and sapogenins: The present invention discloses compositions based on certain furostanol saponins and sapogenins that reduce sebum production. These compounds are useful for the reduction of excess sebum associated with dermatological disorders such as acne, dandruff, and body malodor.... Agent: Shyam K. Gupta Bioderm Research

20070041925 - Skin and hair care preparation containing a combination of protein hydrolyzates: The invention relates to cosmetic preparations, especially hair care preparations or hair care products, containing protein hydrolysates of silk, pashmina, cashmere wool, merino wool and/or mohair, mussel thread extracts, so-called bysuss threads, and sericin and/or sericin hydrolysates. The preparations are mild for skin and hair and lead to an improvement... Agent: Greenblum & Bernstein, P.L.C

20070041926 - Mixture, comprising a surfactant and a cosurfactant: A mixture comprising a surfactant and a cosurfactant is proposed wherein the cosurfactant used is an amphiphilic comb polymer having a backbone with two or more side chains attached to the backbone, where the side chains differ from one another and/or the side chains differ from the backbone in their... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070041921 - Method for relaxing hair: A method of relaxing naturally curly hair that comprises: A) carrying out a hair treatment session that comprises the steps of: i) applying to the hair, an alkaline hair relaxer comprising an active hydroxide, ii) allowing the relaxer to remain on the hair for a total period of less than... Agent: Unilever Intellectual Property Group

20070041927 - Skin cleansing agent, particularly for removing printing inks and/or soiling caused by ink: b) 30 to 70 wt.-% of at least one polyethylene glycol of general formula H—O—(CH2CH2—O)nH, wherein n is an integer of from 1 to 150, c) 1 to 30 wt.-% of at least one fatty alcohol polyglycol ether, d) 0.1 to 5 wt.-% of at least one complexing agent, e)... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070041922 - Compositions for treating keratinous surfaces: A cosmetic composition comprising a extract having an extract of Acmella Oleracea in a cosmetically acceptable carrier, and use of such cosmetic compositions in improving skin conditions associated with aging such as wrinkles, fine lines, laxity, mottled pigmentation, and sallowness.... Agent: Julie Blackburn Revlon Consumer Products Corporation

20070041931 - Compositions comprising soy products and dioic acids: This invention relates to topical compositions comprising soy products and dioic acids and their use in skin lightening, against hyperpigmentation and, in particular, against skin spots.... Agent: Philip S. Johnson Johnson & Johnson

20070041935 - Conformable solvent-based bandage and coating material: Liquid hemostatic coating materials comprise a cyanoacrylate monomer and a solvent system comprising a volatile, non-reactive liquid that is non-stinging and non-irritating to a user. The material forms a coating or bandage in the form of a film that when applied and adhered to a surface or to the skin... Agent: Akerman Senterfitt

20070041936 - Homogeneous preparations of il-28 and il-29: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity... Agent: Zymogenetics, Inc. Intellectual Property Department

20070041932 - Conjugate for gene transfer comprising oligonucleotide and hydrophilic polymer, polyelectrolyte complex micelles formed from the conjugate, and methods for preparation thereof: Disclosed is a conjugate for gene transfer, which is capable of being used for treatment of incurable diseases, comprising an oligonucleotide intended to be transferred into target cells and a hydrophilic polymer, wherein an end of the oligonucleotide is covalently conjugated to the hydrophilic polymer. Also, the present invention discloses... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070041934 - Dendrimer based compositions and methods of using the same: The present invention relates to novel therapeutic and diagnostic dendrimers. In particular, the present invention is directed to dendrimer based compositions and systems for use in disease diagnosis and therapy (e.g., cancer diagnosis and therapy). The compositions and systems comprise one or more components for targeting, imaging, sensing, and/or providing... Agent: Medlen & Carroll, LLP Suite 350

20070041933 - Functionally diverse macromolecules and their synthesis: Functionally diverse macromolecules and synthetic routes for obtaining the same are disclosed. In certain embodiments, the synthesis proceeds in a divergent manner. In other embodiments, the routes rely on the differential reactivity of monomeric electrophilic triazine building blocks that display protected or unprotected groups. This diversity permits the facile introduction... Agent: Fulbright & Jaworski L.L.P.

20070041937 - G-csf derivative for inducing immunological tolerance: The invention relates to a method, composition and use thereof for inducing immunological tolerance, in particular transplantation tolerance in a recipient and self-tolerance in a patient. Tolerance is preferably induced by administering a G-CSF derivative, or biologically active fragment, homolog or variant thereof, in particular peg-G-CSF, to a transplantation donor.... Agent: Leydig Voit & Mayer, Ltd

20070041939 - Modified cytokines for use in cancer therapy: Cytokine derivatives capable of homing the tumoral vessels and the antigen presenting cells and the use thereof as antitumoral agents.... Agent: Foley And Lardner LLP Suite 500

20070041938 - Stable aqueous solutions of granulocyte macrophage colony-stimulating factor: The invention provides formulations of GM-CSF that comprise chelating agents. The chelating agents stabilize the GM-CSF against N-terminal degradation and allow for rapid absorption of GM-CSF upon administration.... Agent: Seed Intellectual Property Law Group PLLC

20070041940 - Methods of treating cancer using il-21: Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a... Agent: Zymogenetics, Inc. Intellectual Property Department

20070041943 - Expression of virus entry inhibitors and recombinant aav thereof: The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver genes encoding human immunodeficiency virus entry inhibitors to target cells in mammals.... Agent: Marshall, Gerstein & Borun LLP

20070041945 - Novel method for down-regulation of amyloid: A method for in vivo down-regulation of amyloid protein in an animal, including a human being, the method comprising effecting presentation to the animal's immune system of an immunogenically effective amount of at least one amyloidogenic polypeptide or subsequence thereof which has been formulated so that immunization of the animal... Agent: Birch Stewart Kolasch & Birch

20070041941 - Nucleic acid sequences encoding and compositions comrpising ige signal peptide and/or il-15 and methods for using the same: Fusion proteins and nucleic acid molecules encoding fusion proteins are disclosed. Fusion proteins comprising non-IL-15 signal peptide linked to IL-15 protein sequences and fusion proteins comprising an IgE signal peptide linked to non-IgE protein sequences are disclosed. Vectors comprising such nucleic acid molecules; and to host cells comprising such vectors... Agent: Cozen O'connor, P.C.

20070041946 - Serotype of adenovirus and uses thereof: Adenovirus serotypes differ in their natural tropism. The adenovirus serotypes 2, 4, 5 and 7 all have a natural affiliation towards lung epithelia and other respiratory tissues. In contrast, serotypes 40 and 41 have a natural affiliation towards the gastrointestinal tract. The serotypes described, differ in at least capsid proteins... Agent: Trask Britt

20070041944 - Treating tumors by enh dislocation of id proteins: The invention provides methods for the therapy of cancer that are directed towards preventing or inhibiting Id function. The present methods are based on contacting neoplastic or tumor cells with agents that can translocate an Id protein to the cytoplasm and/or sequester an Id protein in the cytoplasm, thereby preventing... Agent: Wilmerhale/columbia University

20070041947 - Use of a lentiviral vector in the treatment of pain: Provided is a method for treating and/or preventing pain, in which a vector system is administered such that an EOI is delivered to a DRG of the subject. Also provided is a method for delivering an EOI to the spinal cord using such a vector system. Further provided is a... Agent: Frommer Lawrence & Haug

20070041942 - Use of calcium binding proteins to improve cardiac contractile function: Methods useful in the regulation of myocardial contraction are disclosed. The methods are useful in the regulation of heart function. The invention reveals that sorcin overexpression enhances cardiac contractile performance and establishes the concept of sorcin as a regulator of myocardial contractility. The invention also provides screening assays that allow... Agent: Dla Piper US LLP

20070041957 - Stimulation of cellular regeneration and differentiation in the inner ear: The present invention provides methods for stimulating the formation of inner ear cells, including inner ear sensory hair cells and inner ear support cells. The methods of the present invention damage and/or kill inner ear cells, and stimulate the formation of new, inner ear cells.... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20070041954 - Compositions of placentally-derived stem cells for the treatment of cancer: Disclosed are preparations of placentally-derived stem cells and compositions useful for the treatment of cancer. Said stem cells and compositions function through inducing a “guided differentiation” program in cancer cells, thereby reducing malignancy. Further extension of the invention pertains to augmenting ability of administered cells to induce differentiation through the... Agent: Knobbe Martens Olson & Bear LLP

20070041951 - Differentiation of non-insulin producing cells into insulin producing cells by glp-1 or exendin-4 and uses thereof: The present invention relates to a population of insulin producing cells made by a process comprising contacting non-insulin producing cells with a growth factor selected from the group consisting of GLP-1 or Exendin-4, growth factors having amino acid sequences substantially homologous to GLP-1 or Exendin-4, and fragments thereof. The present... Agent: National Institute Of Health C/o Needle & Rosenberg, P.C.

20070041955 - Hedgehog signaling promotes the formation of three dimensional cartilage matrices: The present invention provides methods and compositions for promoting the formation of three dimensional cartilage matrices. The present invention further provides methods of treating diseases and injuries involving cartilage and bone using the three dimensional cartilage matrices provided herein.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070041950 - Method and device for selective addition of a bioactive agent to a multi-phase implant: A method and device for assembling a multi-phase implant for insertion into a patient defect site that spans more than one tissue type. The assembly device comprises a base and cover portion for constructing a two-phase implant separated by a membrane. A repeating intermediate portion that connects the base and... Agent: Greenlee Winner And Sullivan P C

20070041948 - Method for culturing and proliferating hematopoietic stem cells and progenitor cells using human endometrial cells: Disclosed herein is a method for culturing and proliferating hematopoietic stem cells or progenitor cells. The method comprises co-culturing the hematopoietic stem cells or the progenitor cells with human endometrial stromal cells so as to promote the expansion of hematopoietic stem cell-derived CD34+ cells or the growth of the progenitor... Agent: Intellectual Property / Technology Law

20070041953 - Smooth muscle progenitor cells: Purified populations of smooth muscle progenitor cells are provided as well as methods of making and using the cells.... Agent: Fish & Richardson P.C.

20070041952 - Three-dimensional fiber scaffolds for tissue engineering: A tissue restoration implant adapted for use with a pre-determined tissue, and methods of making and using the same. The tissue restoration implant adapted for use with a pre-determined tissue can include a three-dimensional fiber scaffold, the scaffold comprising at least three systems of fibers; wherein two of the three... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20070041949 - Ultrasonic modification of soft tissue matrices: The present invention provides a method of, and apparatus for, utilising ultrasonic energy so as to mechanically disrupt the collagenous architecture of biological matrices in a controlled manner so that the tissue can be rapidly recellularised in continuous form. The present invention also provides for the production of tissue matrices... Agent: Myers Bigel Sibley & Sajovec

20070041956 - Vaccine immunotherapy for immune suppressed patients: A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naïve T-cells and restoring T-cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naïve T-cells and exposing the naïve T-cells to endogenous or exogenous antigens at an appropriate site.... Agent: Kenneth I. Kohn Kohn & Associates

20070041958 - Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the enzyme peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the enzyme peptides, and methods of identifying... Agent: Celera Genomics Attn: Wayne Montgomery, Vice Pres, Intel Property

20070041959 - Poly-pegylated protease inhibitors: Disclosed are compounds that comprise: (i) a Kunitz domain polypeptide that comprises a Kunitz domain that binds to and inhibits a protease; and (ii) a plurality of polyethylene glycol moieties attached to the Kunitz domain polypeptide. Each accessible primary amine of the Kunitz domain polypeptide can be attached to one... Agent: Fish & Richardson PC

20070041960 - Apparatus and methods for enzymatic debridement of skin lesions: An apparatus for debridement of devitalized tissue in skin lesions, that includes a plurality of height- and angle-adjustable inlet tubes and at least one outlet tube and a member that forms an occlusive seal around a skin lesion. The plurality of inlet tubes is adapted for directing a continuous stream... Agent: Winston & Strawn LLP Patent Department

20070041962 - Method of promoting healing of a tympanic membrane perforation: The present invention relates to the use of plasminogen and plasmin as agents for enhancing healing of tympanic membrane perforations or other wounds, and for reducing scars or necrotic tissue forming during wound healing. The invention also relates to a method for screening of compounds which enhance wound healing by... Agent: Darby & Darby P.C.

20070041961 - Ultrasound target vessel occlusion using microbubbles: Selective occlusion of a blood vessel is achieved by selectively damaging endothelial cells at a target location in the blood vessel, resulting in the formation of a fibrin clot proximate to the damaged endothelial cells. Additional fibrinogen can then be introduced into the blood vessel if occlusion is not achieved,... Agent: Law Offices Of Ronald M Anderson

20070041963 - Human secreted proteins: The present invention relates to human secreted polypeptides, and isolated nucleic acid molecules encoding said polypeptides, useful for diagnosing and treating diseases, disorders, and/or conditions related to said human secreted proteins. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors,... Agent: Human Genome Sciences Inc Intellectual Property Dept.

20070041965 - Novel dermatophagoides nucleic acid molecules, proteins and uses thereof: The present invention relates to high molecular weight Dermatophagoides proteins, nucleic acid molecules encoding such proteins, and therapeutic and diagnostic reagents derived from such proteins.... Agent: Heska Corporation Intellectual Property Dept.

20070041966 - Polypeptides including modified constant regions: Disclosed are processes for producing a variant polypeptide (e.g. antibodies) having increased binding affinity for an FcγR, which processes comprise modifying the polypeptides by substitution of the amino acid at position 268 of a human IgG CH2 region for a non-native polar or charged amino acid e.g. Gin, Asn, Glu,... Agent: Nixon & Vanderhye, PC

20070041964 - Wisp polypeptides and nucleic acids encoding same: Wnt-1-Induced Secreted Proteins (WISPs) are provided, whose genes are induced at least by Wnt-1. Also provided are nucleic acid molecules encoding those polypeptides, as well as vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides fused to heterologous polypeptide sequences, antibodies which bind to... Agent: Heller Ehrman LLP

20070041967 - Igg fc fragment for a drug carrier and method for the preparation thereof: Disclosed is an IgG Fc fragment useful as a drug carrier. Also, the present invention discloses a recombinant vector expressing the IgG Fc fragment, a transformant transformed with the recombinant vector, and a method of preparing an IgG Fc fragment, comprising culturing the transformant. When conjugated to a certain drug,... Agent: Seed Intellectual Property Law Group PLLC

20070041968 - Methods of inducing an immune response: Novel genes designated and set forth in FIG. 2 and their respective encoded proteins, and variants thereof, are described wherein a gene of the invention exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers such as those listed in Table I. Consequently, of gene... Agent: Agensys C/o Morrison & Foerster LLP

20070041969 - Apo-2dcr: Novel polypeptides, designated Apo-2DcR, which are capable of binding Apo-2 ligand are provided. Compositions including Apo-2DcR chimeras, nucleic acid encoding Apo-2DcR, and antibodies to Apo-2DcR are also provided.... Agent: Genentech, Inc.

20070041970 - Ns4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders: The present invention is directed to novel polypeptides NS4 and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the... Agent: Genentech, Inc.

20070041971 - Methods for predicting development of auto-immune diseases and treatment of same: The present invention provides a new method for the prediction of, or diagnosis of, auto-immune diseases, thereby alerting the subject to the presence of, or propensity to develop, an auto-immune disease so that preventative or therapeutic regiments may be initiated or changed so as to treat, modulate or prevent expansion... Agent: Morgan Lewis & Bockius LLP

20070041972 - Antibodies and fusion proteins that include engineered constant regions: Antibodies and/or fusion proteins contain a region that includes an IgG2-derived portion IgG4-derived portion.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070041973 - Compositions and methods for treating, preventing and/or reversing type-1 diabetes: The present invention relates generally compounds, compositions, combinations, kits, and methods for treatment; prevention, suppression, and/or delaying the onset of type 1 diabetes, or reversal of type 1 diabetes.... Agent: Howrey LLP

20070041974 - Cytokine zalpha11 ligand antibodies: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller... Agent: Zymogenetics, Inc. Intellectual Property Department

20070041975 - Homogeneous preparations of il-28 and il-29: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity... Agent: Zymogenetics, Inc. Intellectual Property Department

20070041976 - Methods and compositions relating to anti-interleukin-4 receptor antibodies: Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 antagonist to a patient afflicted with such a condition. Suitable IL-4 antagonists include, but are not limited to, IL-4 receptors (such as a soluble human IL-4 receptor), antibodies that bind IL-4, antibodies that bind IL-4R, IL-4 muteins that... Agent: Immunex Corporation Law Department

20070041978 - Bispecific antibody substituting for functional proteins: The present inventors succeeded in constructing bispecific antibodies, which bind to both the blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X, and functionally substitute for blood coagulation factor VIII/activated blood coagulation factor VIII which enhances the enzymatic reaction.... Agent: Fish & Richardson PC

20070041979 - Proteolysis resistant antibody preparations: Antibody preparations with substantially homogeneous and unsialylated glycoforms, such as G0 and G2, are prepared by enzymatic treatment, expression under certain conditions, use of particular host cells, and contact with serum. These antibody preparations resist cleavage by proteases, such as papain, ficin, bromolein, pepsin, a matrix metalloproteinase, such as MMP-7,... Agent: Philip S. Johnson Johnson & Johnson

20070041977 - Single-chain antibody acting against 37 kda/67 kda laminin receptor as tools for the diagnosis and therapy of prion diseases and cancer, production and use thereof: Single-chain antibodies are described which specifically recognize both the 37 kDa precursor form of the laminin receptor (37 kDa LRP) and the 67 kDa high-affinity form of the laminin receptor (67 kDa LR), and pharmaceutical and diagnostic compositions which contain these single-chain antibodies.... Agent: Breiner & Breiner, L.L.C.

20070041980 - Ca6 antigen-specific cytotoxic conjugate and methods of using the same: Cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the... Agent: Sughrue Mion, PLLC

20070041981 - Compositions and methods for altering immune function: The present invention relates to molecules that stabilize and/or enhance CD154 activity, compositions comprising these molecules, methods for using these molecules and compositions (e.g., pharmaceutical compositions) comprising them. Specifically, the molecules can be used for enhancing immune function (e.g., enhancing Th1 cytokine expression), stimulating immune responses, and/or treating certain disorders... Agent: Medlen & Carroll, LLP

20070041982 - Ilt3 binding molecules and uses therefor: The present invention provides binding molecules that specifically bind to ILT3, e.g., human ILT3 (hILT3), on antigen presenting cells, such as for example, monocytes, macrophages and dendritic cells (DC), e.g., monocyte-derived dendritic cells (MDDC). The binding molecules of the invention are characterized by binding to hILT3 with high affinity and... Agent: Lahive & Cockfield, LLP

20070041983 - Method for treating tumors using anti-osteopontin antibodies: The present invention is directed to compositions of matter useful for the treatment of tumor in mammals and to methods of using those compositions of matter for the same.... Agent: Genentech, Inc.

20070041984 - Novel methods of cancer diagnosis and therapy targeted against a cancer stem line: Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer treatment and reduce the likelihood of clinical relapse after treatment.... Agent: Jones Day

20070041985 - Modulation of the poliovirus receptor function: The present invention relates to the identification, the isolation and the use of molecules interfering with the function(s) mediated by the poliovirus receptor (PVR) on cells. The molecules can be used for the treatment of cells having a metastatic potential, metastasis and cancer. Further methods are provided that are useful... Agent: David S Resnick Nixon Peabody

20070041986 - Synthetic polysaccharide antigens for immunological intervention in disease: Provided are synthetic polysaccharide antigens (SPAs) with anti-inflammatory or inflammatory immunomodulatory properties, depending on their structure. Also provided are compositions comprising these SPAs, and methods of using these SPAs and compositions to either prevent or treat inflammatory pathologies, or diseases or conditions susceptible to treatment with inflammatory immunomodulators, by using... Agent: Eli Lilly & Company

20070041987 - Fragments or polymers of albumin with tunable vascular residence time for use in therapeutic delivery and vaccine development: An isolated fusion protein is provided which is a conjugate of a therapeutic polypeptide and an albumin fragment, such as a fragment including an individual domain or subdomain of albumin, or a polymer of albumin (e.g., dimers, trimers, etc.) and which is used to optimize the half-life of that therapeutic... Agent: Stites & Harbison PLLC

20070041990 - Circovirus sequences associated with piglet weight loss disease (pwd): The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a... Agent: Bingham, Mccutchen LLP

20070041989 - Circovirus sequences associated with piglet weight loss disease (pwd): The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a... Agent: Bingham, Mccutchen LLP

20070041988 - Nucleic acid and amino acid sequences of infectious salmon anaemia virus and their use as vaccines: The present invention provides the use of nucleic acid sequences and/or amino acid sequences in the preparation of a vaccine for the protection of fish against infectious salmon anaemia virus. Specifically, such vaccines contain at least one nucleic acid sequence which is derived from ISAV or synthetically prepared analogues thereof,... Agent: Novartis Corporate Intellectual Property

20070041991 - Babesia vaccines: The invention relates to Babesia proteins of a 28 kDa protein family and to immunogenic fragments of such proteins, to nucleic acids encoding such proteins or fragments, to cDNA fragments, recombinant DNA molecules, live recombinant carriers, or host cells comprising such nucleic acids, to vaccines, to methods for the preparation... Agent: Intervet Inc. Patent Department

20070041992 - Compositions and methods for inactivating or suppressing inflammatory cells: Methods are provided for reducing the activity or function of an inflammatory cell by contacting a cell with, or administering to a subject in need thereof, an effective amount of a circumsporozoite protein or homolog thereof, or a fragment thereof. Methods of treating an inflammatory disease, or an autoimmune disease... Agent: Klauber & Jackson

20070041993 - Compositions and methods for symptomatic relief: An herbal formula provides symptomatic relief for various diseases and especially for patients diagnosed with AIDS/ARC. Particularly preferred formulae include at least part of at least four plants selected from the group consisting of Panax ginseng, Angelica sinensis, Astralagus membranaceus, Ligustrum lucidum, Sophora flavescens, Trichosanthes kirilowii, Agrimonia pilosa, Ganoderma lucidum,... Agent: Robert D. Fish Rutan & Tucker LLP

20070041994 - Compositions and methods for treating prostate disorders: Compositions and methods are described for the treatment of prostatitis, benign prostatic hypertrophy, and prostate cancer. The compositions contain either aqueous extracts or dried mixtures of selenium- and zinc-enriched cannabis plant material, shiitake mushrooms, and maitake mushrooms. The compositions are effective in treating prostate disorders by alleviating pain and voiding... Agent: Janet M. Kerr

20070041995 - Oral compositions for hiv-infected subjects: The invention relates to oral compositions comprising yeast cells that can produce a healthful benefit in a subject infected with human immunodeficiency virus. The invention also relates to methods for manufacturing the oral compositions, and methods of use thereof.... Agent: John J Byrne Suite 504

20070041996 - Aromatase activating agent: The present invention is directed to an aromatase activating agent containing a plant selected from among mulberry bark, ginseng, cucumber, and phellodendron bark; or chlorella; or an extract of any of these ingredients. The aromatase activating agent of the present invention is highly safe to the human body, and useful... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070041997 - Bacterial virulence factors and uses thereof: The invention relates to, in part, secreted proteins of bacterial pathogens and methods for their use. More specifically, the invention provides in part several new common secreted proteins for A/E pathogens. In some embodiments of the invention, these polypeptides and nucleic acid molecules encoding these polypeptides, or portions thereof, are... Agent: Woodcock Washburn LLP

20070042000 - Porcine reproductive and respiratory syndrome vaccine based on isolate ja-142: Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of... Agent: Erickson & Kleypas, L.L.C.

20070041999 - Production of multivalent virus like particles: The present invention is directed to the production and in vitro assembly of recombinant viral capsid proteins into virus like particles. In particular, the present invention provides rapid, scalable, and cost efficient methods for the production of multivalent virus like particles utilizing separate populations of capsid fusion peptides containing differing... Agent: King & Spalding LLP

20070041998 - Use of alum and a th1 immune response inducing adjuvant for enhancing immune responses: The invention relates to the use of Alum for the preparation of a drug for enhancing an antigen-specific type 1 immune response against an antigen in the presence of a type 1 inducing adjuvant.... Agent: Fulbright & Jaworski L.L.P.

20070042002 - Influenza recombinant subunit vaccine: The invention provides influenza proteins, including subunit proteins and immunogenic compositions that can be utilized, with or without adjuvants, as vaccines to protect against influenza infection in animal models and humans. The recombinant proteins are expressed from transformed insect cells that contain integrated copies of the appropriate expression cassettes in... Agent: Paradise Patent Services, Inc. Attn: George Darby

20070042001 - Influenza recombinant subunit vaccine: The invention provides influenza proteins, including subunit proteins and immunogenic compositions that can be utilized, with or without adjuvants, as vaccines to protect against influenza infection in animal models and humans. The recombinant proteins are expressed from transformed insect cells that contain integrated copies of the appropriate expression cassettes in... Agent: Paradise Patent Services, Inc. Attn: George Darby

20070042003 - Method of effecting a mammalian model of sepsis, severe sepsis, or septic shock: A method of effecting a model of sepsis, severe sepsis, or septic shock in a mammalian subject which utilizes the step of introducing particulate or vesicle associated iNOS into the body of the mammalian subject. Prior to or during such introduction, an innate immune system activator may be introduced into... Agent: Theodore J. Bielen Jr.

20070042004 - Methods of treating a bacterial infection using f. tularensis lipopolysaccharide: The present invention relates to the ability of Francisella tularensis LVS lipopolysaccharide (LPS) to confer protection in a subject against a subsequent bacterial infection. Accordingly, the invention provides methods of treating and preventing bacterial infection in a subject by administering F. tularensis LPS to the subject. The invention also relates... Agent: Castellano Malm PLLC

20070042005 - Pharmaceutical composition comprising fungal cell or fragment thereof: The present invention relates to compositions, methods and uses of such compositions, the compositions comprising a pharmaceutically active compound and a non-encapsulating adjuvant, wherein the adjuvant comprises a fungal cell or a fragment thereof.... Agent: Boyle Fredrickson Newholm Stein & Gratz, S.c.

20070042008 - Compositions containing phosphatidylcholine and essential fatty acids: The invention discloses pharmaneutical compositions comprising a phospholipid formulation that is fluidized with an oil composition containing a pre-determined ratio of omega 6 and omega 3 fatty acids. In particular the invention discloses phosphatidylcholine compositions that are fluidized with a pre-determined ratio of linoleic acid and alpha linolenic acid.... Agent: Law Offices Of Khalilian Sira, LLC

20070042006 - Stable carprofen composition: A stable solvent-based composition is described which is particularly useful in warm blooded animals such as dogs. The composition comprises a therapeutically effective amount of carprofen, one or more polyols, one or more stabilising agents and optionally, one or more co-solvents.... Agent: Sonnenschein Nath & Rosenthal LLP

20070042007 - Topical composition for delivery of salicylate esters: The present invention provides a self-emulsifiable composition and a stable topical emulsion comprising same, which comprises salicylate esters, oils and surfactants and which does not require organic solvents. The invention also provides methods for manufacturing the compositions. The topical compositions of the invention can be used to enhance delivery of... Agent: Mccarthy Tetrault LLP

20070042009 - Topical composition for delivery of salicylates: The present invention provides a self-emulsifiable composition and a stable topical emulsion comprising same, which comprises salicylate, oils and surfactants and which does not require organic solvents. The invention also provides methods for manufacturing the compositions. The topical compositions of the invention can be used to enhance delivery of salicylates... Agent: Mccarthy Tetrault LLP

20070042010 - Compositions containing amines and use thereof to treat acne or reduce the appearance of oil or pores on the skin: e

20070042012 - Game attracting substance and a method for applying: A Game Attracting Substance and a Method for Applying such substance comprised of a container, a solution of game attractant scent in a non-liquid sprayable foam or gel and a release mechanism whereby the contents of the container, the non-liquid foam or get containing the game attracting scent solution can... Agent: Walter A. Reiter, Iii

20070042013 - Long acting injectable formulations: The application relates to long acting injectable (LAI) formulations for combating ectoparasites and endoparasites in mammals. In particular, this invention provides for a LAI formulation comprising a subcutaneously volatile solvent, a biologically acceptable polymer, a bioactive agents and optionally one or more anti-ectoparasitically or anti-endoparasitically acceptable additive or excipient. Surprisingly,... Agent: Judy Jarecki-black,ph.d,j.d. Merial Ltd.

20070042011 - Soil-fumigant-containing solid material: A soil-fumigant-containing solid material containing not less than 60 and not more than 85 weight % of a soil fumigant, not less than 0.5 and not more than 15 weight % of gelatin, not less than 0 and not more than 10 weight % of an inorganic mineral, not less... Agent: Buchanan, Ingersoll & Rooney PC

20070042014 - Combination of a serotonin reuptake inhibitor and loxapine: The present invention relates to the use of a combination of Loxapine and a serotonin reuptake inhibitor (SRI), for the treatment of depression and other affective disorders.... Agent: Darby & Darby P.C.

20070042015 - Coating composition for polymeric surfaces comprising serpin or serpin derivatives: The invention relates generally to a coating composition for a polymeric surface, methods for coating a polymeric surface, methods for preparing coated medical devices, polymeric surfaces coated with the coating composition, and medical devices comprising the coating composition. In particular, a coating composition for association with a polymeric surface, preferably... Agent: Millen, White, Zelano & Branigan, P.C.

20070042017 - Medical device with coating that promotes endothelial cell adherence and differentiation: Compositions and methods are provided for producing a medical device such as a stent, a stent graft, a synthetic vascular graft, heart valves, coated with a biocompatible matrix which incorporates antibodies, antibody fragments, or small molecules, which recognize, bind to and/or interact with a progenitor cell surface antigen to immobilize... Agent: Kelley Drye & Warren LLP

20070042016 - Methods and systems for treating injured cardiac tissue: Methods and systems are disclosed for treating injury to cardiac tissue by delivering a composition which provides structural support to the cardiac tissue. The composition helps to prevent chamber remodeling by providing structural reinforcement of the tissue or structural reinforcement of the tissue combined with biological therapy. The structurally reinforcing... Agent: Medtronic Vascular, Inc.IPLegal Department

20070042018 - Absorbable endo-urological devices and applications therefor: This invention deals with an absorbable/disintegratable endo-urological stent and applicators for introduction into biological conduits, including such as urethras and ureters, with said stent comprising a fiber-reinforced, multicomponent tube made of polyesters having a range of physicochemical properties.... Agent: Leigh P. Gregory Attorney At Law

20070042020 - Composition for the treatment of dysfunctional energy metabolism syndrome: A nutritional composition for the treatment of syndromes related to dysfunctional energy metabolism is provided. The composition comprises a combination of L-carnitine, acetyl-L-carnitine, pantothenate and niacinamide. Methods of treatment of dysfunctional energy metabolism are also disclosed.... Agent: The Webb Law Firm, P.C.

20070042019 - Method of treating or preventing chronic wounds and a complete nutritional composition comprising glycine and/or leucine for use therein: The invention relates to a method for the treatment and/or prevention of chronic wounds, said method comprising enterally administering to a patient a composition wherein protein represents between 10 and 40% of the total caloric content of the composition; carbohydrate represents between 15 and 90% of the total caloric content... Agent: The Webb Law Firm, P.C.

20070042021 - Nutritional composition against side effects of chemotherapy of radiotherapy: The present invention relates to a nutritional composition suitable for patients undergoing chemotherapy and/or radiation such as cancer patients. The composition, which may be in powder or liquid form, comprises casein and whey proteins, TGF-β and free glutamine.... Agent: Bell, Boyd & Lloyd LLC

20070042022 - Liquid formulations of ractopamine: Described is a soluble stable liquid formulation, process for preparing, and a method of using the soluble stable liquid formulation comprising ractopamine or a physiologically acceptable salt thereof, a liquid nonionic cosolvent, and water.... Agent: Eli Lilly & Company

20070042023 - Dissolvable film: Dissolvable films are described for the administration of an active ingredient. The film comprises degraded pectin and at least one other filming forming ingredient. The film can carry actives such as medicaments, flavors, seasonings, scents and the like.... Agent: National Starch And Chemical Company

20070042025 - Carboxymethylated cellulosic wound dressing garment: A body shaped wound dressing wherein the dressing is a knitted or woven garment comprising a cellulosic yarn, which garment has been carboxymethylated at least in parts of its wound contacting surface.... Agent: Bristol-myers Squibb Company

20070042024 - Wound dressing material: A material for use as a wound dressing, the material being in the form of a roll and comprising gel forming fibers and the material having lines of longitudinal stitching.... Agent: Bristol-myers Squibb Company

20070042026 - Prophylactic and therapeutic treatment of topical and transdermal drug-induced skin reactions: Botanically derived anti-irritants for prophylactic and therapeutic treatment of adverse skin reactions from application of transdermal or topical drug delivery system, permits the effective administration of a drug from a delivery system in which the drug, of a component of the delivery system comprises a skin irritant; and the delivery... Agent: Law Offices Of Nancy A. Bird

20070042027 - Water soluble anesthetic in an oral patch of hydrophilic gums: An oral patch for treating toothaches and oral lesions, including mouth ulcers (canker sores/aphthous ulcers) with water soluble topical anesthetics such as dyclonine hydrochloride. In one embodiment, the patch is made by depositing blobs of wet mixture including anesthetic, muco-adhesive hydrocolloids such as collagen, and bingers onto flat sheets. The... Agent: Graybeal, Jackson, Haley LLP

20070042028 - Plaster causing reduced skin irritation: A plaster containing an active ingredient for the transdermal administration of a pharmaceutical active ingredient, having a removable protective film and an adhesive layer. The plaster includes at least one compound that is contained in the adhesive layer or lies adjacent the adhesive layer between the adhesive layer and the... Agent: Crowell & Moring LLP Intellectual Property Group

20070042029 - Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (vegf-r): The present invention relates to nucleic acid molecules which modulate the synthesis, expression and/or stability of an mRNA encoding one or more receptors of vascular endothelial growth factor, such as flt-1 and KDR. Nucleic acid molecules and methods for the inhibition of angiogenesis and treatment of cancer and ocular diseases... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070042030 - Preparation for the application of agents in mini-droplets: The invention relates to a preparation for the application of agents in the form of minuscule droplets of fluid, in particular provided with membrane-like structures consisting of one or several layers of amphiphilic molecules, or an amphiphilic carrier substance, in particular for transporting the agent into and through natural barriers... Agent: Edwards & Angell, LLP

20070042032 - Self forming, thermodynamically stable liposomes and their applications: Certain diacylglycerol-polyethyleneglycol (DAG-PEG) lipids are especially useful for forming thermodynamically stable liposomes. Such liposomes are useful for a variety of purposes, including the delivery of therapeutic agents.... Agent: Thelen Reid & Priest, LLP

20070042031 - Systems and methods for manufacturing liposomes: The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. A therapeutic agent, such as nucleic acid,... Agent: Townsend And Townsend And Crew, LLP

20070042036 - Fat-soluble drug composition: The present invention aims at providing a fat-soluble drug composition having improved absorbability of the fat-soluble component in the living body and being stable as a formulation, specifically a fat-soluble drug composition for capsules. The present invention relates to a fat-soluble drug composition comprising a fat-soluble component and an emulsifier,... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070042034 - High drug load formulations and dosage forms: The invention relates to high drug load formulations containing (R)-2-(2-fluoro-4-biphenylyl)propionic acid as an active pharmaceutical ingredient.... Agent: Myriad Genetics Inc. Intellecutal Property Department

20070042033 - Pantoprazole multiparticulate formulations: Pantoprazole sodium multiparticulates are described which avoid sticking to nasogastric and gastronomy tubes. The pantoprazole multiparticulates have a spheroid core of pantoprazole or an enantiomer thereof, or a salt thereof, a surfactant, and a disintegrant; a sub coat which is comprised of hydroxypropyl methylcellulose (hypromellose) and water, an enteric coat... Agent: Howson And Howson Cathy A. Kodroff

20070042035 - Soft capsule: It is an object of the present invention to provide a capsule anti-sticking agent which can provide excellent anti-sticking effect on a soft capsule without impairing various properties such as water activity, disintegration property and safety, a coated soft capsule of high quality which is coated with the capsule anti-sticking... Agent: John L. Cordani Carmody & Torrance LLP

20070042037 - Pharmaceutical composition containing levodopa and carbidopa: An oral solid pharmaceutical composition for constant and prolonged release of a levodopa/carbidopa combination, for use in the treatment of Parkinson disease.... Agent: Young & Thompson

20070042039 - Calcium carbonate granulation: Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet... Agent: King & Spalding

20070042038 - Progestin co-micronized with a surfactant, pharmaceutical composition comprising same, methods for making same and uses thereof: The invention concerns a progestin co-micronized with a surfactant and a pharmaceutical composition comprising said gestagenic. The invention also concerns methods for preparing same.... Agent: Foley And Lardner LLP Suite 500

20070042041 - Drug-surfactant complexes for sustained release: The invention involves sustained-release pharmaceutical compositions containing a water-soluble ionic small molecule pharmaceutical agent complexed with an oppositely charged surfactant, particularly a natural bile surfactant. The complexes are sustained-release ionic complexes. The complexes release the ionic pharmaceutical agents into aqueous solution slowly and with zero-order kinetics. Thus, they can be... Agent: Hugh Mctavish Mctavish Patent Firm

20070042042 - Metformin tablet with sustained release and method for preparing the same: The present invention relates to a metformin tablet with sustained release and a method for preparing the same, more particularly to an improved metformin tablet with sustained release prepared by manufacturing a composition comprising metformin, which is an active ingredient for treatment of insulin-independent diabetes, and a matrix capable of... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20070042040 - Methods and compositions using gonadotropin hormone releasing hormone: The present invention relates to compositions comprising two sustained release formulations, the first being capable of releasing a gonadotropin releasing hormone composition and the second an estrogenic composition. The compositions of the invention can be employed for an improved androgen deprivation therapy of prostate cancer, in which therapy loss of... Agent: Nixon & Vanderhye, PC

20070042043 - Pellet formulations of acid-labile benzimidazonle compounds: They comprise insert granules of sugar/starch which are: initially coated with a non-alkaline active layer having the benzimidazole compound (omeprazole, lansoprazole, pantoprazole, rabeprazole, etc.), sodium and/potassium salts of acids of formula R—O—SO3H wherein R is an alkyl radical of a (C6-C20)-fatty acid (preferably sodium lauryl sulfate), (C6-C20)-fatty acids (preferably oleic... Agent: Hensley Kim & Edgington, LLC

20070042044 - Matrix compositions for controlled delivery of drug substances: A novel matrix composition for pharmaceutical use. The matrix composition has been designed so that it is especially suitable in those situation where an improved bioavailability is desired and/or in those situation where a slightly or insoluble active substance is employed. Accordingly, a controlled release pharmaceutical composition for oral use... Agent: Foley And Lardner LLP Suite 500

20070042045 - Multilayer dosage form comprising a matrix that influences release of a modulatory substance: d) an outer controlling layer comprising at least 60% by weight of one or a mixture of a plurality of (meth)acrylate copolymers composed of 98 to 85 C1 to C4 alkyl esters of (meth)acrylic acid and 2 to 15% by weight of methacrylate monomers with a quaternary ammonium group in... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070042046 - Methods for the treatment of cancer: The invention provides the use of a pharmaceutical compositions comprising a cytotoxic drug and a porous carrier material in methods for the treatment of cancer by chemo-brachytherapy, in particular intra-tumoural administration.... Agent: Nixon & Vanderhye, PC

20070042048 - Devices, compositions and methods for the pulmonary delivery of aerosolized medicaments: According to the subject invention, dispersible dry powder pharmaceutical-based compositions are provided, including methods for their manufacture and dry powder dispersion devices. A dispersible dry powder pharmaceutical-based composition is one having a moisture content of less than about 10% by weight (% w) water, usually below about 5% w and... Agent: Fish & Richardson P.C.

20070042049 - Nanoparticulate benidipine compositions: The present invention relates to nanoparticulate benidipine compositions having improved bioavailability. The compositions comprise benidipine particles having an effective average particle size of less than about 2000 nm and may be useful in the prevention and treatment of hypertension, renal parenchymal hypertension and angina pectoris.... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner LLP

20070042050 - Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression: Polynucleotides encoding at least one immunizing antigen whose expression is controlled by a promoter derived from a gene encoding a co-stimulatory molecule are provided. The polynucleotides may also encode adjuvants. Compositions comprising at least one immunizing agent and at least one cytokine that enhance dendritic cell stimulation and/or survival are... Agent: Foley And Lardner LLP Suite 500

20070042047 - Vaccines: The present invention relates to the novel nucleic acid constructs, useful in nucleic acid vaccination protocols for the treatment and prophylaxis of MUC-1 expressing tumours. In particular, the construct comprises a fusion between a heat shock protein gene HSP70, typically from Mycobacterium tuberculosis and MUCl-1 or derivative thereof. The invention... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070042051 - Remedy ointment for piles and their manufacturing method: A remedy ointment for piles includes the following steps; forming a base-mixture which include collecting a spawn of a swellfish and a starfish and powdering the same; forming a mixture which is obtained by mixing the powder of a starfish and a swellfish spawn obtained by the above step with... Agent: Jordan And Hamburg LLP

20070042052 - Inorganic antibacterial agents containing high valent silver and preparation method thereof: The present invention provides inorganic antibacterial agents containing high valent silver, which are characterized by containing 2-6% by weight divalent silver, trivalent silver or tetravalent silver based on the total weight of the antibacterial agents, wherein said high valent silver is introduced onto the solid carriers by ion exchanges.... Agent: Raymond Y Chan

20070042054 - Functional aphrodisiac rolled herbal bidis and cigarettes: An herbal formulation comprising the synergistic combination of fiber/powder/granules of the aerial parts of at least two plants selected from the group comprising Marticaria chamomilla, Hygrophila auriculata, Aquilaria agallocha, Valeriana wallichii, Nordostachys jatamansi, Artemisia pallen, Papaver somniferum(mainlyleaf), Evolvulus alsinoides, Ficus benghalensis, Echinops echinatus, Lobelia nicotianaefolia, Mucuna pruriens, Tribulus terrestris and... Agent: Ohlandt, Greeley, Ruggiero & Perle, LLP

20070042055 - Herbal formulations and cigarettes containing same useful in controlling body weight: The present invention relates to the an herbal formulation comprising a combination of fiber, powder, and/or granules of aerial parts of plants selected from Hemedesmus indicus, Acorus calamus, Murraya Koenigii, Alpinia galanga, Papaver somniferum, Amorphophallus campanulatus, Hygrophila auriculata, Hygrophila schulli, Cuminum cyminum, Apium graveolens, Colocasia esculenta. The present invention further... Agent: Kenyon & Kenyon LLP

20070042053 - Medicinal herbal composition for treating infection: Herbal compositions derived from Kenyan plants are provided for the treatment of HIV and other infectious diseases. The herbal compositions can include the extracts of up to 14 plants, including the root of Dovyalis abyssinica and Clutia robusta. Also provided are methods for extracting alkaloids and other compounds from the... Agent: Foley & Lardner LLP

20070042056 - Anti-stress agent: The present invention provides an anti-stress agent which can effectively prevent or alleviate various symptoms caused by stress and which is safe and easily taken or ingested. The anti-stress agent comprises an aroma component of coffee or teas as an active ingredient.... Agent: Drinker Biddle & Reath (dc)

20070042057 - Compositions for the treatment and prevention of diabetes mellitus: Compositions comprising a catechin as found in green tea, e.g., epigallocatechin gallate, and ligand which activates the peroxisome proliferatoractivated receptor gamma (PPAR-gamma are useful for the treatment and prevention of diabetes mellitus).... Agent: Stephen M Haracz Bryan Cave

20070042058 - Delivery system for appetite suppressant: The invention relates to a topical delivery system suitable for application to the lips, comprising at least one naturally occurring oil, at least one naturally occurring wax, and at least one naturally occurring diet aid. The invention also relates to a method for controlling weight in an individual by applying... Agent: The Estee Lauder Cos, Inc

20070042059 - Methods for modulating eicosanoid metabolism: The inventive subject matter relates to methods for modulating an eicosanoid metabolic process in cells of an animal in need thereof, which comprises administering to the animal an amount of the inventive compositions effective for regulating the activity of an eicosanoid oxygenase. In particular, the inventive subject matter relates to... Agent: Nath & Associates

20070042060 - Methods to treat one or all of the defined etiologies of female sexual dysfunction: The U.S. Food and Drug Administration defines the four separate components of Female Sexual Dysfunction (FSD) to be decreased sexual desire, decreased sexual arousal, dyspareunia (pain with intercourse), and persistent difficulty in achieving or inability to achieve orgasm (anorgasmia). To establish a diagnosis of FSD, these components must be associated... Agent: Donald N. Halgren

20070042061 - Anti-inflammatory activity of phenethylisothiocyanate (peitc) and the barbarea verna seed preparation containing this compound: The subject of this invention is the anti-inflammatory activity of a formulation of Barbarea verna (upland cress, early winter cress, or winter cress) seed preparation (BSP) containing phenethylisothiocyanate as its main active ingredient. BSP is a promising anti-inflammatory agent, which can be used for treatment of many inflammation-related conditions, including... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20070042062 - Novel anti-diabetic herbal formulation: The invention provides a novel herbal preparation comprises of Glycine max active fraction containing 7S globulin protein extract, Curcuma longa and Zingiber officinale Linn. rhizome extract used in treatment of diabetes and diabetic related diseases.... Agent: Ladas & Parry

20070042063 - Protein kinase modulation by hops and acacia products: Botanical compounds to modulate kinase activity are disclosed. The compounds and methods disclosed also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively. The compositions contain at least one fraction isolated or derived from hops or Acacia.... Agent: Mcdermott Will & Emery LLP Attn: Intellectual Property Deptartment

20070042064 - Extracts of durian fruit for use in skin care compositions: The present invention relates to compositions comprising extracts of Durio zibethinus. The compositions of the present invention are useful for improving the appearance, texture, and/or moisture of mammalian skin. In particular, the compositions of the present invention decrease inflammation in the skin, inhibit matrix metalloprotease-9, which degrades skin proteins such... Agent: In Re: Alticor Inc. 28533 Brinks, Hofer, Gilson & Lione

20070036717 - Chemoradiotherapy with ts-1/camptothecins: An antitumor agent for chemoradiotherapy of rectal cancer comprising a combination of TS-1 (a combination drug of tegafur, gimeracil, and oteracil potassium at a 1:0.4:1 molar ratio) and CPT-11 (irinotecan hydrochloride). The antitumor agent of the invention can achieve marked tumor volume reduction without causing major side effects, especially by... Agent: Sughrue Mion, PLLC

20070036716 - Methods of making radiolabeled tracers and precursors thereof: The present disclosure relates to a solid-phase process for the production of radiolabeled tracers, in particular for the production of 18F-labeled compounds which may be used as Positron Emission Tomography (PET) radiolabeled tracers. The disclosure also relates to radiopharmaceutical kits comprising precursors to the radiolabeled tracers, which can be converted... Agent: Louis J. Wille Bristol-myers Squibb Company

20070036714 - Porphyrin derivatives, methods for obtaining same, and use thereof in radioimmunotherapy: The invention concerns compounds of general formula (I), wherein: when A forms a chain with C, called A-C chain, of formula (1): —X—Y—C6H4-(CH2)n1-C(Z,W)—(CH2)n2-C6H4-Y—X—, then B forms a chain with D, the chain of above formula (1), called A-C and B-D chains located independently of each other, above (position alpha )... Agent: Young & Thompson

20070036718 - Radiolabelled phenylethyl imidazole carboxylic acid ester derivatives: Halogenated carboxylic ester derivatives of phenylethyl imidazole, and their method of preparation are disclosed. Radio-halogenated forms of these compounds are ideally suited for positron-imaging of the adrenal glands, as it is known that these compounds demonstrate a selective and high rate of accumulation in the adrenals. The method of preparing... Agent: Lerner Greenberg Stemer LLP

20070036715 - Tc-labeled arylpiperazine derivatives for imaging serotonin receptor: l

20070036719 - Prostate cancer diagnosis and treatment: The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting,... Agent: Bereskin And Parr

20070036720 - Radiolabelled metal transport protein as imaging agent: A 99mcTc labeled metal transport protein, products and uses thereof in imaging and especially detecting the presence of high energy/iron uptake tissues such as a tumour within a mammalian body are provided.... Agent: Myers Bigel Sibley & Sajovec

20070036721 - Methods and compositions for in vivo inflammation monitoring: Disclosed are methods and materials for detecting inflammation using in vivo and in vitro monitoring, as well as methods of reducing inflammation. Also disclosed are composition related to in vivo monitoring of inflammation, as well as transgenic animals and cell lines useful for such.... Agent: Needle & Rosenberg, P.C.

20070036727 - Adducts between magnetic resonance shift reagents and substrates containing exchangeable protons for \"cest\" applications: Disclosed are CEST paramagnetic agents comprising a substrate (SH) containing mobile protons bonded to a para-magnetic chelate (SR) containing a metal selected from iron (11) (high-spin configuration), iron (111), cobalt (11), rhodium (11), copper (11), nickel (11), cerium (111), praseodymium (111), neodymium (111), dysprosium (111), erbium (111), terbium (111), holmium... Agent: Kramer Levin Naftalis & Frankel LLP

20070036728 - A method of transdermal drug delivery using hyaluronic acid nanoparticles: The present invention relates to the development of a hyaluronic acid and hyaluronic acid hybrid nanoparticle systems for the administration of active molecules, peptides, DNA and/or other hydrophilic or hydrophobic molecules, the composition of hyaluronic acid and hyaluronic acid hybrid nanoparticle systems, and the procedure for their development and use.... Agent: Smith Hopen, Pa

20070036729 - Compositions containing magnetic iron oxide particles, and use of said compositions in imaging methods: The present invention relates to complexes which contain magnetic iron oxide particles in a pharmaceutically acceptable shell, said particles having a diameter of 20 nm to 1 μm with an overall particle diameter/core diameter ratio of less than 6, and to the use of these complexes in magnetic particle imaging... Agent: Millen, White, Zelano & Branigan, P.C.

20070036722 - Separation processes: Separation of target material from a liquid sample is achieved by coupling the target to targetable encapsulated gas microbubbles, allowing the microbubbles and coupled target to float to the surface of the sample to form a floating microbubble/target layer, and separating this layer from the sample. In a positive separation... Agent: Ge Healthcare, IncIPDepartment

20070036726 - Eye treatment: The invention relates to a method of diagnosing the eye and to methods for subsequent treatment following such diagnosis. The method involves diagnosing a deficiency in the anatomy and performance of the upper eyelid recognizing the impact of this deficiency during blinking on problems such as dry eye, contact lens... Agent: Robert G. Rosenthal

20070036725 - Imaging of protease activity in live cells using activity based probes: Methods and materials for the imaging of cells containing active proteases such as cathepsin are disclosed. The present materials include activity based probes that bind to an enzyme and are subsequently cleaved. Cleavage results in a fluorescent signal due to removal of a quenching group which, when present on the... Agent: Peters Verny Jones & Schmitt, L.L.P.

20070036723 - Kinematic adhesive fluorescence measurement patch: A kinematic adhesive fluorescence measurement patch for use with a fluorescent light-emitting bead implanted within a user's body includes an adhesive plate for removable adhesion to the user's body and an optical plate. The optical plate includes a rigid member with a light emitter and light detectors attached thereto. The... Agent: Philip S. Johnson Johnson & Johnson

20070036724 - Non-isotopic detection of osteoblastic activity in vivo using modified bisphosphonates: The present invention is directed to a non-isotopic methods for the in vitro and in vivo detection of hydroxyapatite-positive cells and structures.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070036730 - Cellulose derivatives: Stable microdispersed polyanhydroglucuronic acid and salts thereof contain in their polymeric chain from 8 to 30 percent by weight of carboxyl groups, at least 80 percent by weight of these groups being of the uronic type, at most 5 percent by weight of carbonyl groups including intra- and inter-molecular 2,6... Agent: Jacobson Holman PLLC

20070036731 - Topical delivery with a carrier fluid: Aerosol spray formulations capable of delivering high concentrations of active agent-containing materials and/or excipient are described herein. The formulation contains a carrier fluid, a propellant, and a therapeutic, prophylactic, consmeticeutical and/or inert solid suspended, dissolved, or dispersed in the formulation. The active ingredient may be any pharmaceutically active agent, but... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070036733 - Sensation masking composition: The present invention provides masking compositions that include a lower alkyl carboxylic acid, e.g. acetic acid. Also provided is a masking composition that includes (a) a lower alkyl carboxylic acid (e.g. acetic acid), a warming sensate (e.g. vanillin or vanillyl butyl ether) and/or a cooling sensate (e.g. menthol or isopulegol).... Agent: Darby & Darby P.C.

20070036732 - Stable topiramate formulations: Bi- or multi-phasic tablets comprising an effective amount of a moisture sensitive active ingredient, which in particular is topiramate, wherein at least one of the phases co